Lessons from the RV144 Thai Phase III HIV-1 vaccine trial and the search for correlates of protection

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 423-427

  Kim, Jerome H ^a   Excler, Jean Louis ^a,b   Michael, Nelson L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

antibody dependent cytotoxicity; correlates of risk; efficacy; envelope; HIV vaccine; neutralizing antibody; nonneutralizing antibody

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THAILAND; VACCINATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; THAILAND;

EID: 84921350295     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-052912-123749     Document Type: Article

References (96)

1. UNAIDS 2013. Report on the global AIDS epidemic. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/unaids-global-report-2013-en.pdf
2. Nitayaphan S, Ngauy V, O'Connell R, et al. 2012. HIV epidemic in Asia: optimizing and expanding vaccine development. Expert Rev. Vaccines 11:805-19
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-74
4. Grant RM, Lama JR, Anderson PL, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-99
5. Baeten JM, Donnell D, Ndase P, et al. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367:399-410
6. Choopanya K, Martin M, Suntharasamai P, et al. 2013. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381:2083-90
7. Van Damme L, Corneli A, Ahmed K, et al. 2012. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367:411-22
8. Fauci AS, MarstonHD. 2014. Ending AIDS-Is anHIV vaccine necessary?. N. Engl. J.Med. 370:495-98
9. Haynes BF, McElrathMJ. 2013. Progress inHIV-1 vaccine development. Curr. Opin. HIV AIDS 8:326-32
10. Hemelaar J, Gouws E, Ghys PD, et al. 2011. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25:679-89
11. McBurney SP, Ross TM. 2008. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev. Vaccines 7:1405-17
12. Moir S, Chun TW, Fauci AS. 2011. Pathogenicmechanisms of HIV disease. Annu. Rev. Pathol. 6:223-48
13. Burton DR, Ahmed R, BarouchDH, et al. 2012. A blueprint forHIV vaccine discovery. Cell HostMicrobe 12:396-407
14. Haynes BF, KelsoeG, Harrison SC, et al. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30:423-33
15. Plotkin SA, Gilbert PB. 2012. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54:1615-17
16. Plotkin SA. 2013. Complex correlates of protection after vaccination. Clin. Infect. Dis. 56:1458-65
17. Mascola JR. 2007. HIV/AIDS: allied responses. Nature 449:29-30
18. Burton DR, Hessell AJ, Keele BF, et al. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. USA 108:11181-86
19. Blankson JN. 2011. The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine?. Curr. Opin. HIV AIDS 6:147-50
20. Berman PW, Gregory TJ, Riddle L, et al. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622-25
21. Girard M, Kieny MP, Pinter A, et al. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:542-46
22. Flynn NM, Forthal DN, Harro CD, et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-65
23. Gilbert PB, Peterson ML, Follmann D, et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191:666-77
24. Pitisuttithum P, Gilbert P, Gurwith M, et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-71
25. Buchbinder SP, Mehrotra DV, Duerr A, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-93
26. McElrath MJ, De Rosa SC, Moodie Z, et al. 2008. HIV-1 vaccine-induced immunity in the test-ofconcept Step Study: a case-cohort analysis. Lancet 372:1894-905
27. Rolland M, Tovanabutra S, deCamp AC, et al. 2011. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 17:366-71
28. Fitzgerald DW, Janes H, RobertsonM, et al. 2011. An Ad5-vectoredHIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J. Infect. Dis. 203:765-72
29. Li F, Finnefrock AC, Dubey SA, et al. 2011. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLOS ONE 6:e20479
30. Gray GE, Allen M, Moodie Z, et al. 2011. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-ofconcept phase 2b study. Lancet Infect. Dis. 11:507-15
31. Duerr A, Huang Y, Buchbinder S, et al. 2012. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206:258-66
32. Gray GE, Moodie Z, Metch B, et al. 2014. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-Term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect. Dis. 14:388-96
33. Reynolds MR, Weiler AM, Piaskowski SM, et al. 2012. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 30:4465-75
34. Qureshi H, Ma ZM, Huang Y, et al. 2012. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J. Virol. 86:2239-50
35. Hammer SM, Sobieszczyk ME, Janes H, et al. 2013. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369:2083-92
36. Letvin NL, Rao SS, Montefiori DC, et al. 2011. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3:81ra36
37. Roederer M, Keele BF, Schmidt SD, et al. 2014. Immunological and virological mechanisms of vaccinemediated protection against SIV and HIV. Nature 505:502-8
38. Ministry of Public Health-Thai AIDS Vaccine Evaluation Group. 2011. Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29:4285-92
39. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-20
40. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. 2012. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect. Dis. 12:531-37
41. Rerks-Ngarm S, Paris RM, Chunsutthiwat S, et al. 2013. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J. Infect. Dis. 207:1195-205
42. Whitney JB, Luedemann C, Hraber P, et al. 2009. T-cell vaccination reduces simian immunodeficiency virus levels in semen. J. Virol. 83:10840-43
43. Letvin NL, Mascola JR, Sun Y, et al. 2006. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-33
44. Plotkin SA. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401-9
45. ForthalDN, Gilbert PB, Landucci G, et al. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains ofHIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-603
46. Gilbert P, WangM, WrinT, et al. 2010. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202:595-605
47. Karnasuta C, Paris RM, Cox JH, et al. 2005. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522-29
48. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al. 2004. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190:702-6
49. Haynes BF, Gilbert PB, McElrath MJ, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-86
50. Pinter A, Honnen WJ, Kayman SC, et al. 1998. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16:1803-11
51. Montefiori DC, Karnasuta C, Huang Y, et al. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206:431-41
52. Gottardo R, Bailer RT, Korber BT, et al. 2013. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLOS ONE 8:e75665
53. Zolla-Pazner S, deCamp AC, Cardozo T, et al. 2013. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLOS ONE 8:e53629
54. Alam SM, Liao HX, Tomaras GD, et al. 2013. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-Terminal deletion. J. Virol. 87:1554-68
55. Berman PW, Gray AM, Wrin T, et al. 1997. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J. Infect. Dis. 176:384-97
56. Gilbert PB. 2001. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. Stat. Med. 20:263-79
57. Gilbert PB, WuC, JobesDV. 2008. Genome scanning tests for comparing amino acid sequences between groups. Biometrics 64:198-207
58. Rolland M, Edlefsen PT, Larsen BB, et al. 2012. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490:417-20
59. Zolla-Pazner S, Decamp A, Gilbert PB, et al. 2014. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLOS ONE 9:e87572
60. Karasavvas N, Billings E, Rao M, et al. 2012. The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 28:1444-57
61. Bonsignori M, Pollara J, Moody MA, et al. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86:11521-32
62. Pollara J, Bonsignori M, Moody MA, et al. 2014. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88:7715-26
63. Liu P, Yates NL, ShenX, et al. 2013. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J. Virol. 87:7828-36
64. Rolland MEP, Edlefsen PT, Gottardo R, et al. 2013. Genetic and immunological evidence for a role of Env-V3 antibodies in the RV144 trial. AIDS Res. Hum. Retroviruses 29:A168
65. Brusic V, GottardoR, Kleinstein SH, et al. 2014. Computational resources for high-dimensional immune analysis from the Human Immunology Project Consortium. Nat. Biotechnol. 32:146-48
66. Griffiss JM, Goroff DK. 1983. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J. Immunol. 130:2882-85
67. Tomaras GD, Ferrari G, Shen X, et al. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. USA 110:9019-24
68. Bar KJ, Li H, Chamberland A, et al. 2010. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 84:6241-47
69. YatesNL, Liao HX, Fong Y, et al. 2014. Vaccine-induced Env V1-V2 IgG3 correlates with lowerHIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med. 6:228ra39
70. Roussilhon C, Oeuvray C, Muller-Graf C, et al. 2007. Long-Term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLOS Med. 4:e320
71. Kam YW, Simarmata D, Chow A, et al. 2012. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-Term clinical protection. J. Infect. Dis. 205:1147-54
72. Chung AW, Ghebremichael M, Robinson H, et al. 2014. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6:228ra38
73. Teigler JE, Phogat S, Franchini G, et al. 2014. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J. Virol. 88:1809-14
74. Gorse GJ, Patel GB, Mandava M, et al. 1999. MN and IIIB recombinant glycoprotein 120 vaccineinduced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 15:921-30
75. Banerjee K, Klasse PJ, Sanders RW, et al. 2010. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 26:445-58
76. Ljunggren K, Broliden PA, Morfeldt-Manson L, et al. 1988. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin. Exp. Immunol. 73:343-47
77. Barouch DH, Liu J, Li H, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93
78. Pegu P, VaccariM, Gordon S, et al. 2013. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 87:1708-19
79. Barouch DH, Stephenson KE, Borducchi EN, et al. 2013. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155:531-39
80. Sagar M, Wu X, Lee S, et al. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-98
81. Kwong PD, Wyatt R, Robinson J, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-59
82. Rizzuto CD, Wyatt R, Hernandez-RamosN, et al. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-53
83. Arthos J, Cicala C, Martinelli E, et al. 2008. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9:301-9
84. Bonsignori M, Hwang KK, Chen X, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009
85. Pejchal R, Doores KJ, Walker LM, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-103
86. Walker LM, Phogat SK, Chan-Hui PY, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-89
87. Benjelloun F, Lawrence P, Verrier B, et al. 2012. Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J. Virol. 86:13152-63
88. Hoot S, McGuire AT, Cohen KW, et al. 2013. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLOS Pathog. 9:e1003106
89. Burton DR, Poignard P, Stanfield RL, et al. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337:183-86
90. Thongcharoen P, Suriyanon V, Paris RM, et al. 2007. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defic. Syndr. 46:48-55
91. Hansen SG, Vieville C, Whizin N, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys frommucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-99
92. Ratto-Kim S, Loomis-Price LD, Aronson N, et al. 2003. Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults. J. Acquir. Immune Defic. Syndr. 32:9-17
93. de SouzaMS, Ratto-Kim S, ChuenaromW, et al. 2012. TheThai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 188:5166-76
94. Brehm MA, Shultz LD, Luban J, et al. 2013. Overcoming current limitations in humanized mouse research. J. Infect. Dis. 208(Suppl. 2):S125-30
95. Danner R, Chaudhari SN, Rosenberger J, et al. 2011. Expression ofHLAclass IImolecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLOS ONE 6:e19826
96. Allam AF. 2014. Characterization of B-And T cells in the gut mucosa of humanized DRAG mice during HIV infection. Presented at Keystone Symp. HIV Vaccines-Adaptive Immunity and Beyond, Banff, Alberta, Can.